NCT05922813 is a Phase 1 clinical trial of BMI2004 in Health, Subjective, sponsored by BMI Korea.

Who is sponsoring NCT05922813?

NCT05922813 is sponsored by BMI Korea.

What drugs are being tested in NCT05922813?

Interventions in NCT05922813: BMI2004, 0.9% NaCl.

What condition does NCT05922813 study?

NCT05922813 studies Health, Subjective.

Is NCT05922813 still recruiting?

NCT05922813 is currently completed. Last updated 28 June 2023.

Last reviewed 2023-06-28 · How we verify

NCT05922813

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.

Completed Phase 1 Last updated 28 June 2023

What this trial tests

Phase 1 trial testing BMI2004 in Health, Subjective in 257 participants. Completed in 12 April 2023.

Timeline

30 June 2022

Primary endpoint
10 March 2023

12 April 2023

Quick facts

Lead sponsor	BMI Korea
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	257
Start date	30 June 2022
Primary completion	10 March 2023
Estimated completion	12 April 2023
Sites	1 location across South Korea

Drugs / interventions tested

BMI2004 — full drug profile →
0.9% NaCl

Conditions studied

Health, Subjective — all drugs for Health, Subjective →

Sponsor

BMI Korea — full company profile →

Who can join

19 and older, any sex, with Health, Subjective. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase I clinical trial to evaluate the safety and tolerability of a single-dose administration of BMI2004 Inj. (hyaluronidase, recombinant) in healthy adults

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Health, Subjective

Currently open trials in the same condition.

NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
NCT06829485 — Florida Community-Engaged Research Alliance (FL-CEAL) · NA · recruiting
NCT06392880 — Comparison of Floss Band Application and Mulligan Mobilization · NA · recruiting
NCT06575907 — Health, Functioning, Work, and Experiences of Social and Health Services of Persons With Stroke · active not recruiting
NCT05760001 — The IGNITE for Kids Study on Concentrated Investment in Black Neighborhoods and Child Health and Well-Being · NA · active not recruiting

Other BMI Korea trials

Trials by the same sponsor.

NCT05531968 — Treatment of Moderate to Severe Glabellar Lines (BMI2006) · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05922813 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BMI Korea
Last refreshed: 28 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05922813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing